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INTRODUCTION
Glaucoma represents a group of diseases defined by a characteristic optic neuropathy that is consistent with excavation and undermining of the neural and connective tissue elements of the optic disc and by the eventual development of distinctive patterns of visual dysfunction. 1 As many as 13,4% of blind people in Indonesia suffered from glaucoma. 2 Elevated intraocular pressure (IOP) is one of primary risk factors of glaucoma progression.
Glaucoma patients often come to the clinic with IOP that reach target pressure, but still have glaucoma progression. Twenty-four hours IOP fluctuation affects glaucoma progression. 3 The current goal of glaucoma therapy is reaching target IOP with minimal IOP fluctuation to prevent glaucoma progression. Kumar et al said water drinking test (WDT) can be used as an alternative method to measure peak IOP and IOP fluctuation when patients come to the clinic.
Prostaglandin analogue (PGA) is currently first line drug for primary open angle glaucoma (POAG) that can reduce IOP by 25-32%. Another therapy for POAG is selective laser trabeculoplasty (SLT) that can reduce IOP by 20-25%. 1 Lately, SLT not only used for patients who have maximum tolerance to medical therapy but also used for initial therapy of glaucoma. This study aim to compare PGA and SLT ability to maintain IOP fluctuation on POAG patients.
METHODS
This study was conducted at Dr. Kariadi Hospital from August 2016 until February 2017. Populations of study were POAG patients, which were diagnosed based on gonioscopy examination (open angle), funduscopy examination (cup and disc ratio > 0.3 with glaucomatous excavation, and medialization), the presence of visual field defect based on Humphrey perimetry with MD ≥-6dB within one last year, and had optic nerve and retinal nerve fiber layer (RNFL) thickness OCT examinations within one last year. Glaucoma degree was determined by an average of RNFL thickness. Intervention consist of PGA therapy (latanoprost or travoprost) and 360 0 SLT therapy of trabecular meshwork done by same surgeon. Length of therapy before reaching target IOP was not considered in this study. Samples of study were 30 POAG patients who fulfilled inclusion and exclusion criteria.
Inclusion criteria were 40-69 years old POAG patients who had reach IOP target pressure. Exclusion criteria consist of previous intraocular surgery (ex. cataract extraction, trabeculectomy surgery, etc), the presence of corneal defect, and systemic diseases (ex. congestive heart failure and renal disease).
Water drinking test (WDT) was used to predict peak IOP and IOP fluctuation. Ppatients were asked to drink 1,000 ml mineral water within 10 minutes. Intraocular pressure was measured before WDT and subsequently at 15 minutes, 30 minutes, 45 minutes, and 60 minutes. Peak of IOP and IOP fluctuation were analyzed by SPSS.
RESULTS
Research subjects were POAG patients that divided into PGA group and SLT group. PGA group consist of 26 eyes from 19 patients, while SLT group consist of 16 eyes from 11 patients. Selective laser trabeculoplasty group had fewer patients than PGA group due to laser equipment error since November 2016. Mean age in PGA group was 58.79±6.40 years, while in SLT group was 53.82±7.74 years ( Paired t-test on both group showed IOP pre and post WDT were significantly different in all WDT pairs. This result showed that WDT raised IOP significantly on both group. Peak IOP in PGA group appeared after 15 minutes post WDT, while in SLT group after 30 minutes. When observing presented value by the statistic, it appeared there was a considerable difference in peak IOP between PGA and SLT group, but statistical analysis result indicated that peak of IOP and IOP fluctuation between two groups were not significantly different. This could be influenced by significantly different mean IOP pre WDT that affected peak IOP on both group. It could be concluded that both PGA and SLT had equal potency to control IOP fluctuation.
Nagar et al 6 found that an IOP reduction after treated with latanoprost and SLT 360˚ were not significantly different. Intraocular pressure reduction after treated with latanoprost was >20% in 90% eyes, and >30% in 78% eyes. While IOP reduction after treated with SLT 360˚ was >20% in 82% eyes, and >30% in 59% eyes. The IOP reduction between two groups was not significantly different.
Katz LJ et al 7 also found that IOP reduction between PGA group and SLT group were similar after 9-12 months follow up. Mean IOP reduction in PGA group was 7.0 mmHg, while in SLT group was 6.3 mmHg. Both Nagar et al 6 This study result concluded both therapy had equal potency to control IOP fluctuation, which was different with uther studies. It could be caused by age different of the subjects that influenced patient response to therapy. In Kiddee et al 9 study, mean age of the patients in travoprost group was 62.3 ± 13.1 years, while in SLT group was 68.0 ± 10.0 years. In this study, mean age of patients in PGA group was 58.79 ± 6.40 years, while in SLT group was 53.82 ± 7.74 years.
Nagar et al 8 observed the diurnal curve after 4-6 months follow up of treatment, while this study was at point prevalence using cross sectional design. The different number of subjects between PGA and SLT group in this study could cause different result with previous study.
Water drinking test were raised an IOP significantly on both group. Therefore both PGA and SLT could not prevent IOP fluctuation until normal (2-6 mmHg). However, mean of IOP fluctuation on both groups were lower than IOP fluctuation on glaucoma patients without therapy ( ≥10mmHg). 1 There were some limitations in this study including short period of study, different number of subjects between two groups, the subjects could not represent all of glaucoma degree, no equal period of fasting, no diet recall, and different diurnal time of performing WDT. Besides, there was significantly different IOP pre WDT between two groups that caused difference of peak IOP although not significantly different.
CONCLUSION
There was no significant difference of WDT result (IOP fluctuation) on POAG patients treatment with PGA and with SLT. Prostaglandin Analogue and SLT had equal capability to maintain IOP fluctuation but still higher than normal fluctuation (> 6 mmHg). Prostaglandin analogue or SLT as monotherapy of POAG cannot control IOP normal fluctuation. Additional therapy or combination therapy is required to reach normal IOP fluctuation.
